Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Fast-Tracked Psychedelic Medicines For Depression And PTSD

The Food and Drug Administration has fast-tracked three psychedelic medicines for review, issuing priority vouchers to companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone, a compound related to MDMA, for post-traumatic stress disorder, in a development that could put the first FDA-approved psychedelic medicines on the market as soon as this summer. The vouchers compress the agency’s standard review timeline from the usual 10 to 12 months down to just one to two months, a change the FDA Commissioner said is designed to ensure that red tape does not delay treatments that show genuine promise for conditions that have been notoriously difficult to treat. The three companies that received vouchers are Compass Pathways, the nonprofit Usona Institute, and Otsuka Pharmaceutical, which is acquiring the methylone program. The action followed an executive order signed by President Trump directing the FDA to prioritize psychedelic drugs that have received Breakthrough Therapy designation, a status reserved for treatments showing early evidence of substantial improvement over existing options.

For millions of Americans with treatment-resistant depression, PTSD, and other serious mental health conditions that have not responded to available medications, the move represents a potential turning point in access to a category of medicine that has shown significant clinical results but has remained largely inaccessible for decades. Psilocybin has shown durable antidepressant effects in multiple studies, with some patients maintaining improvement for at least a year after a single treatment course. The FDA also cleared the first-ever clinical study in the United States of noribogaine, a compound derived from the ibogaine plant, as a potential treatment for alcohol use disorder, a condition that affects more than 29 million Americans. The FDA Commissioner said the first psychedelic drug could receive approval by the end of summer, and that the field is moving forward grounded in sound science and rigorous clinical standards.

Source: https://edition.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers

PrevPreviousJurassic Park Star Sam Neill Is Cancer Free

Recent Articles

Happy News

A 13-Year-Old Found A Coin In A Berlin Field And It Just Made History

April 30, 2026

When a 13-year-old boy named Lenny walked through a field in the Spandau district of Berlin in 2025, he noticed a small, unremarkable object half-hidden in the soil and picked it up, correctly sensing it was something worth showing to an expert. When archaeologists at the interactive dig lab PETRI

Read More
Happy News

The Supreme Court Said The Tariffs Were Illegal, Now FedEx And UPS Are Sending Money Back

April 29, 2026

Here is some genuinely good news for your wallet. In February, the U.S. Supreme Court ruled that a sweeping set of tariffs that had been driving up prices on imported goods were unconstitutional — and now the refund process has officially begun. This week, the federal government opened a portal

Read More
Happy News

Amsterdam Is The First Capital City In The World To Ban Fossil Fuel Ads

April 29, 2026

Starting May 1, 2026, the billboards, bus shelters, metro platforms, and tram stops of Amsterdam will be cleared of advertisements for flights, cruises, petrol-powered cars, gas heating contracts, and meat products, as the Dutch capital becomes the first in the world to enforce a legally binding ban on fossil fuel

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.